midazolam
Sponsor COGT · listed as COGT
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
midazolam is a clinical-stage drug asset sponsored by COGT, listed as COGT. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Nov 13, 2026 (day precision, medium confidence), tied to trial NCT05646862. The asset is in Phase 3 and currently active not recruiting, studied in Breast Cancer. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2026-11-13
As disclosedNov 13, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05646862
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorHoffmann-La Roche
Listed asCOGT
Condition(s)Breast Cancer
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More COGT catalysts